Impact of fosaprepitant in the prevention of nausea and emesis in head and neck cancer patients undergoing cisplatin-based chemoradiation: a pilot prospective study and a review of literature.
Chemoradiotherapy
Chemotherapy-induced nausea
Emesis
Fosaprepitant
Head and neck cancer
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
25
05
2023
accepted:
03
01
2024
medline:
18
3
2024
pubmed:
14
2
2024
entrez:
13
2
2024
Statut:
ppublish
Résumé
Cisplatin-based chemoradiotherapy (CRT) is standard treatment for head and neck squamous cell carcinoma (HNSCC). However, IMRT may increase chemotherapy-induced nausea and vomiting (CINV). The purpose of this study is to investigate the effect of fosaprepitant in preventing CINV. An infusion of 150 mg fosaprepitant was given through a 30 min. We assessed acute toxicity using CTCAE v.4 and the incidence of CINV using the FLIE questionnaire. The evaluation of CINV was done at the second and fifth weeks of CRT and 1 week after the end. The EORTC QLQ-HN 43 questionnaire was administered before treatment beginning (baseline), at second (T1) and fifth (T2) weeks. A dosimetric analysis was performed on dorsal nucleus of vagus (DVC) and area postrema (AP). Between March and November 2020, 24 patients were enrolled. No correlation was found between nausea and DVC mean dose (p = 0.573), and AP mean dose (p = 0.869). Based on the FLIE questionnaire, patients reported a mean score of 30.5 for nausea and 30 for vomiting during week 2 and 29.8 for nausea and 29.2 for vomiting during week 5. After treatment ended, the mean scores were 27.4 for nausea and 27.7 for vomiting. All patients completed the EORTC QLQ-HN 43. Significantly higher scores at T2 assessment than baseline were observed. The use of fosaprepitant in preventing CINV reduced incidence of moderate to severe nausea and vomiting. No correlation has been found between nausea and median dose to DVC and AP.
Identifiants
pubmed: 38351333
doi: 10.1007/s11547-024-01757-3
pii: 10.1007/s11547-024-01757-3
pmc: PMC10942929
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
fosaprepitant
6L8OF9XRDC
Antiemetics
0
Antineoplastic Agents
0
Morpholines
0
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-466Informations de copyright
© 2024. The Author(s).
Références
J Clin Epidemiol. 2003 Mar;56(3):221-9
pubmed: 12725876
Support Care Cancer. 2019 Mar;27(3):783-791
pubmed: 30607675
Support Care Cancer. 2014 Feb;22(2):469-77
pubmed: 24141698
Support Care Cancer. 2009 Jan;17(1):23-32
pubmed: 18528717
Radiol Med. 2017 Apr;122(4):303-308
pubmed: 28070838
Med Oncol. 2019 Apr 09;36(5):44
pubmed: 30968205
Radiother Oncol. 2019 Jan;130:113-120
pubmed: 30172454
Support Care Cancer. 2013 Mar;21(3):735-48
pubmed: 22976921
Support Care Cancer. 2019 Jan;27(1):87-95
pubmed: 30284039
Br J Cancer. 2013 Aug 20;109(4):859-65
pubmed: 23860530
Radiother Oncol. 2023 Nov;188:109896
pubmed: 37660751
J Clin Oncol. 2018 Apr 10;36(11):1064-1072
pubmed: 29220295
Radiother Oncol. 2009 Jul;92(1):4-14
pubmed: 19446902
Ann Oncol. 2016 Sep;27(suppl 5):v119-v133
pubmed: 27664248
J Community Support Oncol. 2016 Apr;14(4):141-7
pubmed: 27152512
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S36-41
pubmed: 20171516
Expert Rev Anticancer Ther. 2008 Nov;8(11):1733-42
pubmed: 18983233
Support Care Cancer. 2017 May;25(5):1503-1510
pubmed: 28032216
Head Neck. 2020 Jan;42(1):131-137
pubmed: 31633260
Support Care Cancer. 2018 Feb;26(2):557-564
pubmed: 28871358
J Natl Compr Canc Netw. 2017 Jul;15(7):883-893
pubmed: 28687576
Ann Palliat Med. 2017 Aug;6(Suppl 1):S13-S20
pubmed: 28595433
Support Care Cancer. 2016 Nov;24(11):4633-8
pubmed: 27286875
Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1101-1107
pubmed: 26059352
Eur J Cancer. 2003 Jul;39(10):1395-401
pubmed: 12826042
Eur J Pharmacol. 2014 Jan 5;722:172-9
pubmed: 24157982
J Clin Oncol. 1997 Jan;15(1):103-9
pubmed: 8996130
N Engl J Med. 2008 Jun 5;358(23):2482-94
pubmed: 18525044
Radiother Oncol. 2014 May;111(2):281-8
pubmed: 24746582
J Clin Oncol. 2007 Sep 10;25(26):4096-103
pubmed: 17827459
Support Care Cancer. 2011 Mar;19 Suppl 1:S5-14
pubmed: 20697746
Radiol Med. 2023 Dec;128(12):1571-1579
pubmed: 37642816
J Clin Oncol. 2020 Aug 20;38(24):2782-2797
pubmed: 32658626
Head Neck. 2015 Sep;37(9):1358-67
pubmed: 24832623
Cancer Treat Rev. 2017 Sep;59:79-92
pubmed: 28759822
Support Care Cancer. 2015 Jan;23(1):185-90
pubmed: 25063271
Crit Rev Oncol Hematol. 2016 Mar;99:13-36
pubmed: 26697988
Lancet Oncol. 2016 Apr;17(4):509-518
pubmed: 26952945
J Clin Oncol. 2008 Jul 20;26(21):3582-9
pubmed: 18559875